[1] Berge E, Whiteley W, Audebert H, et al., 2021, European Stroke Organisation (ESO) Guidelines on Intravenous Thrombolysis for Acute Ischaemic Stroke. European Stroke Journal, 6(1): I–LXII.

[2] The GBD 2016 Lifetime Risk of Stroke Collaborators, 2018, Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. New England Journal of Medicine, 379(25): 2429–2437.

[3] Herpich F, Rincon F, 2020, Management of Acute Ischemic Stroke. Critical Care Medicine, 48(11): 1654–1663.

[4] Liu R, Song P, Gu X, et al., 2022, Comprehensive Landscape of Immune Infiltration and Aberrant Pathway Activation in Ischemic Stroke. Frontiers in Immunology, 12: 766724.

[5] Shi K, Tian DC, Li ZG, et al., 2019, Global Brain Inflammation in Stroke. The Lancet Neurology, 18(11): 1058–1066.

[6] Zhang W, Tian T, Gong SX, et al., 2021, Microglia-Associated Neuroinflammation Is a Potential Therapeutic Target for Ischemic Stroke. Neural Regeneration Research, 16(1): 6.

[7] Qin C, Zhou LQ, Ma XT, et al., 2019, Dual Functions of Microglia in Ischemic Stroke. Neuroscience Bulletin, 35(5): 921–933.

[8] Chhor V, Le Charpentier T, Lebon S, et al., 2013, Characterization of Phenotype Markers and Neuronotoxic Potential of Polarised Primary Microglia in Vitro. Brain, Behavior, and Immunity, 32: 70–85.

[9] Chen AQ, Fang Z, Chen XL, et al., 2019, Microglia-Derived TNF-α Mediates Endothelial Necroptosis Aggravating Blood Brain–Barrier Disruption after Ischemic Stroke. Cell Death & Disease, 10(7): 487–505.

[10] Liu W, Qi Z, Li W, et al., 2022, M1 Microglia Induced Neuronal Injury on Ischemic Stroke via Mitochondrial Crosstalk between Microglia and Neurons. Oxidative Medicine and Cellular Longevity, 2022(1): 4335272.

[11] Fan P, Wang S, Chu S, et al., 2023, Time-Dependent Dual Effect of Microglia in Ischemic Stroke. Neurochemistry International, 169: 105584.

[12] Xia CY, Zhang S, Gao Y, et al., 2015, Selective Modulation of Microglia Polarization to M2 Phenotype for Stroke Treatment. International Immunopharmacology, 25(2): 377–382.

[13] Shimizu T, Prinz M, 2025, Microglia across Evolution: From Conserved Origins to Functional Divergence. Cellular & Molecular Immunology, 22(12): 1533–1548.

[14] Kanazawa M, Ninomiya I, Hatakeyama M, et al., 2017, Microglia and Monocytes/Macrophages Polarization Reveal Novel Therapeutic Mechanism against Stroke. International Journal of Molecular Sciences, 18(10): 2135.

[15] Liddelow SA, Guttenplan KA, Clarke LE, et al., 2017, Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia. Nature, 541(7638): 481–487.

[16] Zhang Y, Li J, Zhao Y, et al., 2024, Arresting the Bad Seed: HDAC3 Regulates Proliferation of Different Microglia after Ischemic Stroke. Science Advances, 10(10): eade6900.

[17] Jolivel V, Bicker F, Binamé F, et al., 2015, Perivascular Microglia Promote Blood Vessel Disintegration in the Ischemic Penumbra. Acta Neuropathologica, 129(2): 279–295.

[18] Keren-Shaul H, Spinrad A, Weiner A, et al., 2017, A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell, 169(7): 1276–1290.e17.

[19] Shao L, Chang Y, Liu J, et al., 2024, scRNA-Seq Reveals Age-Dependent Microglial Evolution as a Determinant of Immune Response Following Spinal Cord Injury. Brain Research Bulletin, 219: 111116.

[20] Gelderblom M, Sobey CG, Kleinschnitz C, et al., 2015, Danger Signals in Stroke. Ageing Research Reviews, 24: 77–82.

[21] Jiang L, Xu F, He W, et al., 2016, CD200Fc Reduces TLR4-Mediated Inflammatory Responses in LPS-Induced Rat Primary Microglial Cells via Inhibition of the NF-κB Pathway. Inflammation Research, 65(7): 521–532.

[22] Khoshnavay F, Amirshahrokhi K, Namjoo Z, et al., 2024, Carvedilol Attenuates Inflammatory Reactions of Lipopolysaccharide-Stimulated BV2 Cells and Modulates M1/M2 Polarization of Microglia via Regulating NLRP3, Notch, and PPAR-γ Signaling Pathways. Naunyn-Schmiedeberg’s Archives of Pharmacology, 397(7): 4727–4736.

[23] Shimada K, Crother TR, Karlin J, et al., 2012, Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during Apoptosis. Immunity, 36(3): 401–414.

[24] Swanson KV, Deng M, Ting JPY, 2019, The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics. Nature Reviews Immunology, 19(8): 477–489.

[25] Ye Y, Rao Z, Xie X, et al., 2025, Naoqing Formula Alleviates Cerebral Ischemia/Reperfusion Injury Induced Inflammatory Injury by Regulating Csf3 Mediated JAK/STAT Pathway and Macrophage Polarization. Phytomedicine, 140: 156626.

[26] Guan S, Lu T, Li L, et al., 2025, Targeting Hypercoagulability in Ischemic Stroke Modulates Fibrin-Driven Microglial Polarization via JAK-STAT Pathway. Journal of Neuroinflammation, 22(1): 258–279.

[27] Xie X, Wang F, Ge W, et al., 2023, Scutellarin Attenuates Oxidative Stress and Neuroinflammation in Cerebral Ischemia/Reperfusion Injury through PI3K/Akt-Mediated Nrf2 Signaling Pathways. European Journal of Pharmacology, 957: 175979.

[28] Sun YY, Zhu HJ, Zhao RY, et al., 2023, Remote Ischemic Conditioning Attenuates Oxidative Stress and Inflammation via the Nrf2/HO-1 Pathway in MCAO Mice. Redox Biology, 66: 102852.

[29] Li W, Fan Y, Hussain SA, 2025, Neuroprotective Effects of Sinomenine and Metformin in Diabetic Stroke: Role of NLRP3/Caspase-1 and Mitophagy. Experimental Physiology: EP093135.

[30] Reed S, Taka E, Darling-Reed S, et al., 2025, Neuroprotective Effects of Metformin through the Modulation of Neuroinflammation and Oxidative Stress. Cells, 14(14): 1064.

[31 Jin Q, Cheng J, Liu Y, et al., 2014, Improvement of Functional Recovery by Chronic Metformin Treatment Is Associated with Enhanced Alternative Activation of Microglia/Macrophages and Increased Angiogenesis and Neurogenesis Following Experimental Stroke. Brain, Behavior, and Immunity, 40: 131–142.

[32] Naseh M, Vatanparast J, Rafati A, et al., 2021, The Emerging Role of FTY720 as a Sphingosine 1-Phosphate Analog for the Treatment of Ischemic Stroke: The Cellular and Molecular Mechanisms. Brain and Behavior, 11(6): e02179.

[33] Qin C, Fan WH, Liu Q, et al., 2017, Fingolimod Protects against Ischemic White Matter Damage by Modulating Microglia toward M2 Polarization via STAT3 Pathway. Stroke, 48(12): 3336–3346.

[34] Abdollahi E, Johnston TP, Ghaneifar Z, et al., 2023, Immunomodulatory Therapeutic Effects of Curcumin on M1/M2 Macrophage Polarization in Inflammatory Diseases. Current Molecular Pharmacology, 16(1): 2–14.

[35] Cao X, Pu Y, 2025, Curcumin Regulates Microglia Polarization to Alleviate Ischemic Stroke by Targeting microRNA-205-5p/Kruppel-like Factor 2 (KLF2)/Activating Transcription Factor 2 (ATF2) Axis. Chemical Biology & Drug Design, 105(1): e70050.

[36] Bai Y, Sui R, Zhang L, et al., 2024, Resveratrol Improves Cognitive Function in Post-Stroke Depression Rats by Repressing Inflammatory Reactions and Oxidative Stress via the Nrf2/HO-1 Pathway. Neuroscience, 541: 50–63.

[37] Owjfard M, Rahimian Z, Karimi F, et al., 2024, A Comprehensive Review on the Neuroprotective Potential of Resveratrol in Ischemic Stroke. Heliyon, 10(14): e34121.

[38] Cunningham CJ, Redondo-Castro E, Allan SM, 2018, The Therapeutic Potential of the Mesenchymal Stem Cell Secretome in Ischaemic Stroke. Journal of Cerebral Blood Flow & Metabolism, 38(8): 1276–1292.

[39] Lee JY, Kim E, Choi SM, et al., 2016, Microvesicles from Brain-Extract–Treated Mesenchymal Stem Cells Improve Neurological Functions in a Rat Model of Ischemic Stroke. Scientific Reports, 6(1): 33038.

[40] Nouri Z, Barfar A, Perseh S, et al., 2024, Exosomes as Therapeutic and Drug Delivery Vehicle for Neurodegenerative Diseases. Journal of Nanobiotechnology, 22(1): 463–491.

[41] Dabrowska S, Andrzejewska A, Lukomska B, et al., 2019, Neuroinflammation as a Target for Treatment of Stroke Using Mesenchymal Stem Cells and Extracellular Vesicles. Journal of Neuroinflammation, 16(1): 178–195.

[42] Fu X, Li J, Yang S, et al., 2025, Blood-Brain Barrier Repair: Potential and Challenges of Stem Cells and Exosomes in Stroke Treatment. Frontiers in Cellular Neuroscience, 19: 1536028.

[43] Bao Q, Hu P, Xu Y, et al., 2018, Simultaneous Blood–Brain Barrier Crossing and Protection for Stroke Treatment Based on Edaravone-Loaded Ceria Nanoparticles. ACS Nano, 12(7): 6794–6805.

[44] Qiu Y, Zhang C, Chen A, et al., 2021, Immune Cells in the BBB Disruption after Acute Ischemic Stroke: Targets for Immune Therapy? Frontiers in Immunology, 12: 678744.

[45] Song J, Yang G, Song Y, et al., 2024, Neutrophil Hitchhiking Biomimetic Nanozymes Prime Neuroprotective Effects of Ischemic Stroke in a Tailored “Burning the Bridges” Manner. Advanced Functional Materials, 34(32): 2315275.

[46] Hu K, Ye J, Fan P, et al., 2025, Targeting and Reprogramming Microglial Phagocytosis of Neutrophils by Ginsenoside Rg1 Nanovesicles Promotes Stroke Recovery. Bioactive Materials, 47: 181–197.

[47] Zhao Y, Li Q, Niu J, et al., 2024, Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy. Advanced Materials: 2311803.

[48] Sun S, Lv W, Li S, et al., 2023, Smart Liposomal Nanocarrier Enhanced the Treatment of Ischemic Stroke through Neutrophil Extracellular Traps and Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase-Stimulator of Interferon Genes (cGAS-STING) Pathway Inhibition of Ischemic Penumbra. ACS Nano, 17(18): 17845–17857.

[49] Jin L, Zhu Z, Hong L, et al., 2023, ROS-Responsive 18β-Glycyrrhetic Acid-Conjugated Polymeric Nanoparticles Mediate Neuroprotection in Ischemic Stroke through HMGB1 Inhibition and Microglia Polarization Regulation. Bioactive Materials, 19: 38–49.

[50] Dong Z, Tang L, Zhang Y, et al., 2023, A Homing Peptide Modified Neutrophil Membrane Biomimetic Nanoparticles in Response to ROS/Inflammatory Microenvironment for Precise Targeting Treatment of Ischemic Stroke. Advanced Functional Materials: 2309167.